Literature DB >> 21705951

Are biochemical markers of neuroendocrine tumors coreleased with insulin following local calcium stimulation in patients with insulinomas?

Peter Wiesli1, Heiko Uthoff, Aurel Perren, Thomas Pfammatter, Cornelia Zwimpfer, Heidi Seiler, René Kindhauser, Giatgen A Spinas, Christoph Schmid.   

Abstract

OBJECTIVES: The objective was to test whether chromogranin A (CgA), neuron-specific enolase (NSE), and pancreatic polypeptide (PP) are released from the pancreas during the selective arterial calcium stimulation and hepatic venous sampling test (ASVS) in patients with insulinomas.
METHODS: We determined CgA, NSE, PP, insulin, C-peptide, and proinsulin in blood samples obtained during the ASVS test in 19 patients with insulinomas. Levels following calcium injection into the arteries supplying the tumor were compared with levels following calcium stimulation of arteries supplying healthy pancreatic tissue.
RESULTS: After calcium injection into the artery supplying the insulinoma, a significant 8-fold increase in insulin (range, 2.3-117; P < 0.001), a 3.8-fold increase in C-peptide (1.7-32.4; P < 0.001), and a 1.9-fold increase in proinsulin (0.7-5.3, P < 0.001) were detectable whereas NSE and CgA did not increase. No significant increases in insulin, C-peptide, proinsulin, CgA, and NSE concentrations were found after calcium injection into control arteries. Pancreatic polypeptide increased 1.5-fold (0.8-4.5; P = 0.017) after calcium injection into the tumor artery and 2.4-fold (0.8-7.9; P = 0.016) after injection into the control artery.
CONCLUSIONS: Insulin, C-peptide, and proinsulin are released by insulinoma cells in response to arterial calcium stimulation, whereas CgA and NSE are not released. Also from our study it seems that PP may be released by healthy islet cells after calcium stimulation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21705951     DOI: 10.1097/MPA.0b013e31821ffce1

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  3 in total

1.  Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Franco Grimaldi; Nicola Fazio; Roberto Attanasio; Andrea Frasoldati; Enrico Papini; Francesco Angelini; Roberto Baldelli; Debora Berretti; Sara Bianchetti; Giancarlo Bizzarri; Marco Caputo; Roberto Castello; Nadia Cremonini; Anna Crescenzi; Maria Vittoria Davì; Angela Valentina D'Elia; Antongiulio Faggiano; Stefano Pizzolitto; Annibale Versari; Michele Zini; Guido Rindi; Kjell Oberg
Journal:  J Endocrinol Invest       Date:  2014-07-20       Impact factor: 4.256

2.  Distinct mechanisms of hypoglycaemia in patients with somatostatin-secreting neuroendocrine tumours.

Authors:  Peter Wiesli; Vojtech Pavlicek; Michael Brändle; Thomas Pfammatter; Aurel Perren; Christoph Schmid
Journal:  Endocrinol Diabetes Metab       Date:  2019-06-27

3.  Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas.

Authors:  Xin-Wei Qiao; Ling Qiu; Yuan-Jia Chen; Chang-Ting Meng; Zhao Sun; Chun-Mei Bai; Da-Chun Zhao; Tai-Ping Zhang; Yu-Pei Zhao; Yu-Li Song; Yu-Hong Wang; Jie Chen; Chong-Mei Lu
Journal:  BMC Endocr Disord       Date:  2014-08-07       Impact factor: 2.763

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.